SBR00029
Dansyl labeled polymyxin B
Ready Made Solution, for fluorescent microbial imaging, 1.5 mg/mL in H2O
Synonym(s):
DSL-PMB, DSL-PMX, DSL-PxB
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.76
UNSPSC Code:
51102829
Quality Level
form
ready-to-use solution
availability
not available in China
concentration
1.5 mg/mL in H2O
color
colorless to light brown
suitability
suitable for (Fluorescent detection of gram-negative bacteria), suitable for (Microbiome), suitable for microbiology
mode of action
cell membrane
shipped in
ambient
storage temp.
−20°C
Related Categories
General description
Dansyl Polymyxin B (DSL-PMB) is a fluorescent derivative of Polymyxin B. Polymyxin B is a cationic lipopeptide antibiotic that binds specifically to Gram-negative bacteria. Fluorescent antibiotics are obtained by synthetic conjugation of an antibiotic to a fluorophore.
Dansyl labeled Polymyxin B can be utilized for fluorescent microbial imaging in the fields of Cell Biology and Biochemical research.
Application
DSL-PMB may have been used:
- as a fluorescent probe to study polymyxin mode of action and its pharmacokinetics
- in research and to develop new active derivatives of Polymyxin against multi-drug resistance Gram-negative infections
- to measure LPS binding affinity by fluorometric displacement assay
- Antimicrobial resistance research.
- Bacterial visualization and imaging.
- Parent antibiotic mode of action research and new antibiotic discovery.
- Toxicity studies.
- Research of bacterial infections and tracking its uptake in vivo.
Biochem/physiol Actions
DSL-PMB′s mode of action is in accordance with Polymyxin B activity. However, MIC assays comparing DSL-PMB, and parent Polymyxin B showed a two to three-fold decrease in bacterial activity. Polymyxin B interacts with anionic lipopolysaccharide (LPS) molecules which are located in Gram-negative bacterial outer membrane. This interaction interferes with the outer membrane′s normal function, causing leakage and enhanced uptake of the antibiotic. The resemblance in properties between Polymyxin B and DSL-PMB allows to fluorescently label Gram-negative bacteria and examine intracellular localization and penetration of Polymyxins in Gram-negative bacteria.
Features and Benefits
- High-quality antibiotic suitable for multiple research applications
- Ideal for Cell Biology, Metabolomics, and Biochemical research.
Analysis Note
- Dansyl Labeled Polymyxin B Ready Made Solution is light sensitive.
- It is recommended to avoid freeze-thaw cycles of PMB-DSL Ready Made Solution.
- Dansyl Labeled Polymyxin B Ready Made Solution (1.5 mg/mL) can be diluted 1:50 in PBSX1 (Sigma#D8537) to achieve 30 μg/mL final concentration for staining. The above concentration of DSL-PMB was used for E. coli staining see image.
- Fluorescence Microscopy application: Dansyl Labeled Polymyxin B Ready Made Solution excitation (Ex) wavelength is 330-340nm resulting in emission (Em) range of 540-600nm (λmax=570nm).
Other Notes
For additional information on our range of Biochemicals, please complete this form.
Storage Class
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
涉药品监管产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R A Moore et al.
Antimicrobial agents and chemotherapy, 30(6), 923-926 (1986-12-01)
Pseudomonas cepacia was found to be resistant to the outer membrane-permeabilizing effects of aminoglycoside antibiotics, polymyxin B, and EDTA. Permeabilization of P. cepacia to the fluorescent probe 1-N-phenylnaphthylamine was not achieved at concentrations 100- to 1,000-fold above those required to
R E Hancock
Lancet (London, England), 349(9049), 418-422 (1997-02-08)
The era of the "classical antibiotic" may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest
Vincent H Tam et al.
Antimicrobial agents and chemotherapy, 49(9), 3624-3630 (2005-08-30)
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in vitro pharmacodynamics of PB against four strains of Pseudomonas aeruginosa. Clonal relatedness of the strains
Zakuan Z Deris et al.
Bioconjugate chemistry, 25(4), 750-760 (2014-03-19)
The dry antibiotic development pipeline coupled with the emergence of multidrug resistant Gram-negative 'superbugs' has driven the revival of the polymyxin lipopeptide antibiotics. Polymyxin resistance implies a total lack of antibiotics for the treatment of life-threatening infections. The lack of
Interaction of cationic peptides with bacterial membranes.
S Fidai et al.
Methods in molecular biology (Clifton, N.J.), 78, 187-204 (1997-01-01)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service